A quasi-experimental study finds print-based education improves self-care in type 2 diabetes patients in Nigeria, without measuring glycaemic outcomes. PICO summary and commentary.
Browsing: Type 2 Diabetes
Landmark trials and recent evidence on type 2 diabetes management, glucose-lowering therapy, and outcomes.
A recruitment analysis finds men, Hispanics, and Spanish speakers underenrol at every step of a diabetes exercise trial despite active outreach. PICO summary and commentary.
A 20-week RCT finds empagliflozin improves nerve conduction velocity in diabetic neuropathy but not clinical exam scores, with glycaemic confounding. PICO summary and commentary.
A small unblinded trial finds Huayu Tongluo moxibustion improves cognition and insulin resistance in type 2 diabetes, with high placebo potential. PICO summary and commentary.
The INTE-COMM Lancet trial finds community-based care matches facility care for stable HIV, diabetes, and hypertension in sub-Saharan Africa. PICO summary and expert commentary.
The CREDENCE trial demonstrated that canagliflozin reduced the composite of end-stage kidney disease, doubling of serum creatinine, or renal or cardiovascular death by 30% in patients with type 2 diabetes and albuminuric chronic kidney disease, becoming the first dedicated renal outcomes trial to demonstrate that an SGLT2 inhibitor could substantially slow the progression of diabetic nephropathy.
The DECLARE-TIMI 58 trial demonstrated that dapagliflozin did not reduce 3-point MACE compared with placebo but significantly reduced the composite of cardiovascular death or hospitalisation for heart failure, driven entirely by a 27% reduction in heart failure hospitalisation, in the largest and most broadly representative SGLT2 inhibitor cardiovascular outcomes trial conducted to date.
The CANVAS Programme demonstrated that canagliflozin reduced major adverse cardiovascular events by 14% in patients with type 2 diabetes at high cardiovascular risk, but identified an approximately twofold increase in lower-extremity amputation risk, primarily at the toe or metatarsal level, requiring careful patient selection and monitoring.
The EMPA-REG OUTCOME trial demonstrated that empagliflozin reduced cardiovascular death by 38% and heart failure hospitalisation by 35% in patients with type 2 diabetes and established cardiovascular disease — the first glucose-lowering agent to show a mortality benefit in a cardiovascular outcomes trial.
A three-year follow-up finds most people who reached diabetes remission via intermittent calorie restriction maintained it without ongoing intervention. PICO summary and commentary.